Clinical trial • Phase I • Oncology

BI 3810944 for Melanoma | Solid tumours

Phase I trial of BI 3810944 for Melanoma | Solid tumours. 13 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Melanoma | Solid tumours
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
18-07-2025
First CTIS Authorization Date
14-11-2025

Trial design

Phase I trial across 3 sites in Belgium, Netherlands.

Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
13
Trial Duration For Participant
1404

Recruitment

Planned Sample Size
13
Recruitment Window Months
46

Geography

Total Number Of Sites
3
Total Number Of Participants
13

Belgium

Earliest CTIS Part Ii Submission Date
10-10-2025
Latest Decision Or Authorization Date
14-11-2025
Processing Time Days
35
Number Of Sites
2
Number Of Participants
13

Sites

Site Name
UZ Leuven
Department Name
Medical Oncology Department
Principal Investigator Name
Patrick Schoffski
Principal Investigator Email
patrick.schoffski@uzleuven.be
Contact Person Name
Patrick Schoffski
Contact Person Email
patrick.schoffski@uzleuven.be
Site Name
Cliniques Universitaires Saint-Luc
Department Name
Department of Oncology, route 42
Principal Investigator Name
Jean-François Baurain
Contact Person Name
Jean-François Baurain

Netherlands

Earliest CTIS Part Ii Submission Date
23-10-2025
Latest Decision Or Authorization Date
17-11-2025
Processing Time Days
25
Number Of Sites
1
Number Of Participants
13

Sites

Site Name
Radboud universitair medisch centrum Stichting
Department Name
Medical oncology
Principal Investigator Name
Carla van Herpen
Principal Investigator Email
carla.vanherpen@radboudumc.nl
Contact Person Name
Carla van Herpen
Contact Person Email
carla.vanherpen@radboudumc.nl

Sponsor

Primary sponsor

Full Name
Boehringer Ingelheim International GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
BI 3810944

Related trials

Other published trials that may interest you.